Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 African trypanosomiasis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
2 African trypanosomiasis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
3 AGE-RAGE signaling pathway in diabetic complications 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
4 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
5 Alcoholic liver disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
6 Alcoholic liver disease 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
7 Alzheimer disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
8 Alzheimer disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
9 Amoebiasis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
10 Amoebiasis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
11 Amoebiasis 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
12 Antifolate resistance 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
13 Antifolate resistance 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
14 C-type lectin receptor signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
15 C-type lectin receptor signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
16 Cellular senescence 💬
 [1] IL1A 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
17 Chagas disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
18 Chagas disease 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
19 Coronavirus disease - COVID-19 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
20 Coronavirus disease - COVID-19 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
21 Cytokine-cytokine receptor interaction 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
22 Cytokine-cytokine receptor interaction 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
23 Cytokine-cytokine receptor interaction 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
24 Cytosolic DNA-sensing pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
25 Cytosolic DNA-sensing pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
26 Fluid shear stress and atherosclerosis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
27 Fluid shear stress and atherosclerosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
28 Fluid shear stress and atherosclerosis 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
29 Graft-versus-host disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
30 Graft-versus-host disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
31 Hematopoietic cell lineage 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
32 Hematopoietic cell lineage 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
33 Hematopoietic cell lineage 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
34 Herpes simplex virus 1 infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
35 Herpes simplex virus 1 infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
36 Human cytomegalovirus infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
37 Human cytomegalovirus infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
38 Human cytomegalovirus infection 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
39 Human T-cell leukemia virus 1 infection 💬
 [2] IL1R1, IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
40 IL-17 signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
41 IL-17 signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
42 Inflammatory bowel disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
43 Inflammatory bowel disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
44 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
45 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
46 Inflammatory mediator regulation of TRP channels 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
47 Influenza A 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
48 Influenza A 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
49 Legionellosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
50 Legionellosis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
51 Leishmaniasis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
52 Leishmaniasis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
53 Lipid and atherosclerosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
54 Lipid and atherosclerosis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
55 Malaria 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
56 Malaria 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
57 MAPK signaling pathway 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
58 MAPK signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
59 MAPK signaling pathway 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
60 Measles 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
61 Measles 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
62 Necroptosis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
63 Necroptosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
64 NF-kappa B signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
65 NF-kappa B signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
66 NF-kappa B signaling pathway 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
67 NOD-like receptor signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
68 NOD-like receptor signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
69 Non-alcoholic fatty liver disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
70 Non-alcoholic fatty liver disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
71 Osteoclast differentiation 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
72 Osteoclast differentiation 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
73 Osteoclast differentiation 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
74 Pathogenic Escherichia coli infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
75 Pathogenic Escherichia coli infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
76 Pathogenic Escherichia coli infection 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
77 Pathways of neurodegeneration - multiple diseases 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
78 Pathways of neurodegeneration - multiple diseases 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
79 Pertussis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
80 Pertussis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
81 Prion disease 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
82 Prion disease 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
83 Prostate cancer 💬
 [1] IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
84 Rheumatoid arthritis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
85 Rheumatoid arthritis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
86 Salmonella infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
87 Salmonella infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
88 Shigellosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
89 Shigellosis 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
90 Shigellosis 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
91 Th17 cell differentiation 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
92 Th17 cell differentiation 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
93 Th17 cell differentiation 💬
 [1] IL1R1 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
94 TNF signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
95 TNF signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
96 Toll-like receptor signaling pathway 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
97 Toll-like receptor signaling pathway 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
98 Transcriptional misregulation in cancer 💬
 [1] IL1R2 💬 D02934 💬 Anakinra [18]  2 , 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
99 Tuberculosis 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
100 Tuberculosis 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
101 Type I diabetes mellitus 💬
 [2] IL1A, IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬
102 Type I diabetes mellitus 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
103 Yersinia infection 💬
 [1] IL1B 💬 D09315 💬 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
104 Yersinia infection 💬
 [1] IL1B 💬 D06635 💬 Rilonacept [4] 51, 106, 107, 266 💬

Back to top